What is the evidence for providing parenteral nutrition containing both essential amino acids and nonessential amino acids in AKI?

• A. Early clinical studies suggested that essential amino acids and dextrose could reduce dialysis need; subsequent studies showed no difference between EAA alone and EAA plus nonessential amino acids; formulations providing only EAA are not recommended; Branched chain amino acids have no advantage; Several nonessential amino acids become conditionally essential in AKI.
• B. Essential amino acids alone are superior to any combination with nonessential amino acids.
• C. Branched-chain amino acids provide a clear advantage in AKI PN.
• D. Nonessential amino acids never become conditionally essential in AKI.

Answer: (A)

In AKI, the body is in a highly stressed, catabolic state that changes amino acid needs. Several nonessential amino acids can become conditionally essential, meaning the body may not make enough of them during critical illness. That’s why parenteral nutrition in AKI aims to include both essential and nonessential amino acids—to cover those conditional requirements that arise with kidney injury.

Early studies suggested that giving essential amino acids with dextrose might reduce the need for dialysis, but later research showed no clear difference between regimens that used only essential amino acids and those that added nonessential amino acids. Branched-chain amino acids do not provide a clear advantage in this setting.

So the best-supported takeaway is that nonessential amino acids can become essential in AKI, supporting the inclusion of those amino acids in PN, while simply adding them to an essential-amino-acid regimen does not consistently improve outcomes. This is why PN formulations in AKI commonly provide both essential and nonessential amino acids rather than relying on essential amino acids alone.